Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
1 hedge funds and large institutions have $48K invested in Sonnet BioTherapeutics in 2020 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
50% less funds holding
Funds holding: 2 → 1 (-1)
52% less capital invested
Capital invested by funds: $100K → $48K (-$52K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$34K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$14K |
| 3 |
SI
Stephens Inc
Little Rock,
Arkansas
|
-$6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Truist Financial
Charlotte,
North Carolina
| $15K | – | – | – |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $9K | – | – | – |
|
|
ECM
3
ETrade Capital Management
Arlington,
Virginia
| $7K | – | – | – |
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $7K | – | – | – |
|
5
BlackRock
New York
| $4K | – | – | – |
|
6
Northern Trust
Chicago,
Illinois
| $4K | – | – | – |
|
7
Bank of America
Charlotte,
North Carolina
| $2K | – | – | – |
|
|
8
Renaissance Technologies
New York
| – | -$34K | -1 | Closed |
|
|
9
Citadel Advisors
Miami,
Florida
| – | -$14K | – | – |
|
|
SI
10
Stephens Inc
Little Rock,
Arkansas
| – | -$6K | – | – |
|
|
11
UBS Group
Zurich,
Switzerland
| – | -$2K | – | – |
|
SONN Hedge Fund Activity: Q1 2020 in Review
1 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q1 2020, worth a combined $48K — down 52% from $100K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of SONN and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Renaissance Technologies, exiting entirely with an estimated $34K sold.
- 1 institutional investor held Sonnet BioTherapeutics (SONN) as of Q1 2020, down from 2 in Q4 2019.
- Funds reported $48K of Sonnet BioTherapeutics stock for Q1 2020, down 52% quarter-over-quarter.
- 0 funds opened new Sonnet BioTherapeutics positions in Q1 2020 and 1 closed out, a net change of -1 holder.
- The largest Sonnet BioTherapeutics seller in Q1 2020 was Renaissance Technologies, an estimated $34K sold.
Based on aggregated 13F filings for Q1 2020.